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Many viruses have developed numerous strategies to recruit and take advantage of cellular protein 
degradation pathways to evade the cellular viral immune system. One such virus is the Kaposi´s Sarcoma 
associated herpesvirus (KSHV), first discovered in Kaposi´s Sarcoma lesions found in AIDS patients. 
Latency-Associated Nuclear Antigen (LANA) is a KSHV multifunctional protein responsible for tethering 
viral DNA to the chromosome ensuring maintenance and segregation of the viral genome during cell 
division. Besides its main role of viral maintenance, LANA also physically interacts with several host 
proteins to modulate cell functions. One such function is to recruit the EC5S ubiquitin-ligase complex by 
interacting with Elongin BC complex and Cullin 5 protein, which in turn ubiquitinate substrates such as NF-
κB and p53 to allow persistent viral infection. Like any other post-translation modifications, ubiquitination is 
reversible through deubiquitination enzymes (DUBs). LANA also interacts with ubiquitin specific protease 
7 (USP7), a deubiquitination enzyme involved in regulation of several proteins including p53. Interaction 
with USP7 is made through a conserved peptide motif, which is also present in LANA. This work addresses 
the role of LANA in the recruitment and modulation of the ubiquitination and deubiquitination pathways. 
Despite the continued efforts in uncovering new LANA interacting partners to form a functional EC5S 
ubiquitin-ligase complex, only MHV-68 LANA interacted directly with Elongin BC, other interactions were 
not direct and may require a linker protein. On the other hand, LANA interaction with USP7 was able to be 
analysed by X-ray structure determination. In addition to a conserved P/AxxS motif, a novel Glutamine (Gln) 
residue from KSHV LANA was shown to make a specific interaction with USP7. This Gln residue is also 
present in other herpesvirus protein and hence it might be a conserved motif within herpesviruses.  
Keywords: Kaposi´s sarcoma herpesvirus; Latency-Associated Nuclear Antigen; Ubiquitination; EC5S 









Vários vírus desenvolveram inúmeras estratégias de recrutamento de vias celulares de degradação 
proteíca, para eludir o sistema imunitário. Um exemplo, é o Herpesvírus associado ao sarcoma de kaposi 
(KSHV), tendo sido descoberto no sarcoma de kaposi em pacientes portadores de HIV. O Antigénio 
Nuclear Associado à Latência (LANA) é uma proteína multifuncional deste vírus, responsável pela 
manutenção e segregação do genoma viral durante a divisão celular. Por outro lado, LANA tem a 
capacidade de interagir físicamente com várias proteínas do hospedeiro, de forma a garantir infecção viral 
ininterrupta. Um exemplo concreto é o recrutamento do complexo Ubiquitina-Ligase EC5S, através da 
interação com as proteínas Elongin BC e Cullin 5 que por sua vez têm a capacidade de ubiquitinar diversos 
substratos como NF-κB e p53, para posterior degradação. Tal como acontece em outras modições pós-
traducionais, ubiquitinação é reversível. De forma equivalente, LANA interage com a protease especifica 
de ubiquitina 7 (USP7), responsável pela regulação de várias proteínas através da remoção de cadeias de 
ubiquitina. A interacção entre USP7 e diversos ligandos é feita através de um motivo conservado, também 
presente na sequência de LANA. Este trabalho teve como objetivo ilucidar o papel de recrutamento e as 
interacções estabelecidas entre LANA e o complexo EC5S, como entre LANA e a proteína USP7. Através 
de ensaios de pull down, verificou-se que a proteína LANA do KSHV não é capaz de estabelecer uma 
interação direta com Elongin BC. Por outro lado, a proteína homologa de murine, mLANA, consegue 
interagir diretamente com Elongin BC. Foi ainda possível determinar a estrutura raios-X do complexo 
USP7-LANA e ilucidar as interacções estabelcidas entre estas proteínas. Apesar de USP7 ser 
caracterizado por reconhecer o motivo conservado P/AxxS, um novo motifo QPGPR foi identificado no 
complexo USP7-LANA.  
Palavras-Chave: Herpesvirus Associado ao Sarcoma de Kaposi; Antigénio Nuclear Associado à Latência; 
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The name herpes originated from the Greek word herpein which means to creep, which reflects 
the spreading nature of the skin lesions caused by many herpesvirus types. Of the more than 130 known 
herpesviruses, eight are a leading cause of human viral disease: herpes simplex virus types 1 and 2, 
varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 (variants A and B), human 
herpesvirus 7, Kaposi's sarcoma associated herpesvirus and B virus. Each virus within the family has the 
potential to establish latency in specific host cells, and the latent viral genome may be extra-chromosomal 
or integrated into host cell DNA. A latent virus may be reactivated and enter a replicative cycle at any point 
in time 1. 
Herpesviruses are divided into three sub-families: The α-Herpesviruses characterized by a short 
replicative cycle (hours) and have a broad host range. This sub-family establish latency in neurons and 
consists of herpes simples virus types 1 and 2 and varicella-zoster virus; the β-Herpesviruses, that in 
contrast to α-Herpesviruses, have a long replicative cycle (days) and have a broad host range. 
Cytomegalovirus and human herpesvirus belongs to the β-Herpesviruses and they establish latency in 
macrophages and lymphocytes. Lastly, γ-herpesviruses, such as Epstein-Barr virus and Kaposi´s sarcoma 
associated herpesvirus, have the most restricted range host and establish latency only in lymphocytes 1,2. 
 
1.2. Kaposi´s Sarcoma associated Herpesvirus  
 
Kaposi´s sarcoma (KS) is an infectious cancer that mainly occurs in immunocompromised patients, 
characterized by neoplastic cells and abnormal growth of blood vessels (Figure 1.1). This type of tumour 
mainly affects the skin, mouth and lymph nodes. It is named after the Hungarian dermatologist, Moritz 
Kaposi who discovered it in 1872 3. KS occurs in Europe and the Mediterranean countries (classic KS), 
Africa (endemic KS), immunosuppressed patients (post-transplant KS) and those with acquired immune 
deficiency syndrome (AIDS), and is especially prevalent among those who are infected by human 
immunodeficiency virus (HIV-1) 4,5. 
 
 
Figure 1.1- Kaposi's sarcoma oncogenesis. (a) example of a typical kaposi’s sarcoma skin lesion; (b) 
micrograph of a kaposi sarcoma (hematoxylin and eosin stain) showing the characteristic spindle cells, high 






In 1994 KS was discovered to be caused by a virus from the herpesvirus family, and named 
Kaposi´s sarcoma associated herpesvirus (KSHV) 6. KSHV is the most recently discovered human tumour 
virus. It is the eighth human herpesvirus isolated to date and is thus also named human herpesvirus 8 
(HHV8) 6. It is a large double-stranded DNA virus from the γ-herpesvirus family. Besides being responsible 
for KS lesions, it is also associated with other lymphoproliferative disorders, such as primary effusion 
lymphoma and Multicentric Castleman´s disease 7–9.  
KSHV infection is predominantly latent, and the virus persists in the nuclei of latently infected cells 
as a multiple-copy, covalently closed, extrachromosomal episome 5.  
The murine gammaherpesvirus 68 (MHV-68 or murid herpesvirus 4) is a natural pathogen of small 
rodents (mice, voles and shrews), from the rhadinovirus family 10. It is structurally and functionally related 
to human γ-herpesviruses and readily infects mice, thus providing an ideal mouse model for the 
investigation of γ-herpesvirus pathogenesis 11. The sequence is 118 kb in length flanked by guainine 
cytosine (GC)-rich terminal repeats and exist in a circular episomal form during latency. It is predicted to 
encode 79 ORFs 12.  
All γ-herpesviruses, including EBV, KSHV and MHV-68, encapsidate duplex linear DNA genomes 
in their particles. Upon infection of cells, this DNA is delivered to the nucleus, where it is circularized (largely 
by host enzymatic machinery), generating a closed-circular DNA form that can persist in the nucleus as a 
plasmid 12. 
Similar to other herpesvirus family members, KSHV and MHV-68 display two alternate genetic life 
cycles: the establishment of latency and reactivation from latency, which lead to lytic replication 13,14. The 
transition from latency to lytic replication is controlled by the KSHV replication and transcription activator 
(RTA), encoded by the KSHV gene open reading frame 50 (ORF50) 13,15. 
Lytic replication leads to extensive viral gene expression, virion production, and death of the 
infected cell 13. In contrast, latent infection is characterized by a limited gene expression to a small subset 
of viral latent genes and are often involved in viral episome maintenance, replication and the transformation 
of host cells 16. 
 Establishing latency enables KSHV to sustain a life-long infection and to escape immune 
surveillance 16,17. At least, five viral genes are expressed during latency, the latency-associated nuclear 
antigen (LANA), viral cyclin (v-Cyclin), viral Fas-associated death domain interleukin 1L-converting enzyme 
inhibitory protein (vFLIP) encoded by K13, viral interferon regulatory factors encoded by K10 (vIFN3), and 
kaposin encoded by K12 13,14. 
 
1.3. LANA Protein 
 
Latently expressed viral proteins have been shown to promote tumourigenesis by subverting the 
cellular mechanisms which would normally protect cells from aberrant proliferation; LANA is the 
predominant gene expressed in latent infection and exerts anti-apoptotic and anti-proliferative effects on 
cells by interacting with and inhibiting p53, retinoblastoma protein, and glycogen synthase kinase 3 17. The 
main function of LANA is to tether the viral genome to the chromosome during cell division and allows the 
virus to persist by segregation of the viral DNA to daughter cells. 
LANA is multifunctional and capable of maintaining viral latency through repression of the 
transcriptional activity of RTA (replication and transcription activator) promoter 18. It is also required for DNA 
replication, chromosome tethering, cell cycle regulatory and gene regulatory functions. LANA binds to 
sequences in the virus terminal repeats that are essential for replication of the episomal genomes during 
latency 19.  
The KSHV LANA (kLANA) encoded by open reading frame 73 (ORF73), is a nuclear protein with 
1162 amino acid in length and it was first identified by Western blot as a 222- to 234- kDa protein 20,21. The 
N-terminal domain is separated from its C-terminal domain by a large internal repeat region (Figure 1.2). 
The N-terminal domain of kLANA binds to nucleosome core particles: the proline-rich region contains a 
nuclear localization signal (NLS) and a sequence motif that tethers LANA to chromosomes during mitosis.  
The central domain contains different highly repetitive blocks of acidic amino acids. The acidic 
region close to the C-terminal domain contains a leucine zipper motif that has been demonstrated to be 




Figure 1.2- Schematic representation of KSHV LANA. The N-terminal histone binding domain, nuclear localization 
signal (NLS), Proline rich region, Acidic repeat region, Leucine Zipper and SUMO interaction motif (SIM) are also 
indicated. Numbers indicate amino acid position. Adapted from 23. 
 
kLANA’s C-terminal domain binds to the LANA binding sites (LBS) within the viral terminal repeat 
(TR) in a sequence-specific manner and thus this domain is referred to as DNA-binding domain (DBD) 24–
27. The N-terminal domain and the internal repeat region are predicted to be only poorly structured, in 
contrast the C-terminal domain comprises a stable 3D structure with a strong hydrophobic core. Therefore, 
only the LANA DBD structure was initially solved 28 and more recently the X-ray structure of LANA C-
terminal domain bound to DNA was determined 24. The DNA is bound to the kLANA DBD dimer with 
remarkable asymmetry 24. Despite the great homology, kLANA differs from EBNA1 and E2, both of which 
bind palindromic target sequences in a symmetric fashion 29,30. It was also found that LANA binds to a third 
binding site, the replication element 24, denoted LBS3, to distinguish from LBS1 and LBS2 tethering sites. 
All three sites are located in the KSHV terminal repeat subunit region 24.  
The ORF73 from MHV-68 (mLANA) encodes a much smaller, 314 amino acid, 50 kDa nuclear 
protein which lacks the extensive internal acidic and glutamine-rich repeat region of kLANA. The C-terminal 
region of mLANA, comprising amino acid residues 140 to 263, which is similar to the kLANA DNA-binding 
domain. Similar to kLANA, mLANA was also recently shown to act on TR elements of the MHV-68 genome 
to mediate episome maintenance and to associate with mitotic chromosomes.  
However, kLANA and mLANA DBD interact with its respective LBS regions very differently, with a 
bent and linear conformation, respectively, indicating divergence within KSHV and MHV-68 31. 
 
1.4. Ubiquitin Complex 
 
All intracellular proteins and many extracellular proteins are continually “turning over;” i.e., they are 
being hydrolysed to their constituent amino acids and replaced by new synthesis. Although the continual 
destruction of cell proteins might seem wasteful, this process serves several important regulation functions, 
such as regulation of cell cycle, cell growth and development, transcription, DNA repair, oncogenesis, 
antigen processing and selective degradation of abnormally folded and damaged proteins 32. Individual 
proteins in the nucleus and cytosol, as well as in the endoplasmic reticulum (ER) and mitochondria, are 
degraded at widely differing rates that vary from minutes for some regulatory enzymes to days or weeks for 
proteins such as actin and myosin in skeletal muscle or months for haemoglobin in the red cell. The 
Ubiquitin–proteasome system (UPS) is the principal mechanism for the turnover of short-lived proteins 33–
35. 
Ubiquitin (Ub) is a highly conserved protein in eukaryotes, of small size (8.5 kDa polypeptide) with 
76 amino acids. Cellular proteins destined for degradation are covalently linked to ubiquitin through a 
multistep process known as ubiquitination. Ubiquitination consists of concerted actions of enzymes that link 
chains of the polypeptide co-factor, Ub, onto proteins to mark them for degradation. The presence of 
multiple substrate-linked ubiquitins recruits the 26S proteasome, a 2.5 MDa complex that uses energy 
derived from ATP hydrolysis to unfold the substrate polypeptide chain and translocate it into an interior 
chamber. Having arrived at this site, the substrate is hydrolysed to produce small peptides. Ubiquitin is 
spared from degradation through its release from the substrate (or a substrate fragment) by deubiquitinating 





The Ub–proteasome system comprises two phases. In the first phase (Figure 1.3), Ub is activated 
through the ATP-dependent formation of a thiol ester with a cysteine residue of Ub-activating enzyme (E1), 
then transferred to a cysteine residue of an Ub-conjugating enzyme (E2) before, finally being transferred to 
a lysine residue of the substrate in a reaction catalysed by a Ub-protein ligase (E3). Ub is linked to the 
substrate through an isopeptide bond. For substrates that will be targeted to proteasomes, additional Ub 
molecules are conjugated to the first one to form a branched chain that is also linked through isopeptide 
bonds 33,38.  
In the second phase of the cycle, the proteasome recognizes the substrate via the poly-ubiquitinate 
chain; the substrate is degraded to small peptides in a processed manner, and Ub is regenerated by specific 
deubiquitinating enzymes. Like conjugation, proteasome-catalysed degradation is ATP dependent 33,38. 
The E3 ligase usually determines the substrate specificity, although the E2-conjugating enzyme 
can also play a role in the substrate selection. Thus hundreds of E3/Ub ligases have been identified, while 
there are only few known E1 and E2 enzymes, in mammals. E3 enzymes are currently classified into three 
main classes, with different structural and functional characteristics: the HECT domain family of Ub ligases, 
the Cullin-RING family of Ub ligases, and the U-box containing Ub ligases 38 
Ub contains at least seven lysines (K) and additional residues that can be employed by the Ub 
ligases to generate different types of Ub chains on the target proteins, which, in turn, will interact with 
different downstream factors (Figure 1.3). For instance, it is well established that K-48-based linkages lead 
mainly to the proteasome-mediated degradation of the ubiquitinated protein, while K-63-based Ub chains 
control primarily protein endocytosis, as well as trafficking and enzyme activity 36,39. Moreover, it has been 
demonstrated that Ub can also function to act independently from its proteolytic activity, by regulating 
protein function and protein/protein interaction38,40. 
 
 
Figure 1.3- Schematic representation of the Ub molecule and of the enzymatic cascade leading to protein 
ubiquitination. The seven lysines (K) involved in the process, the ubiquitin-activating enzyme E1, the ubiquitin-
conjugating enzyme E2 and the ubiquitin ligase enzyme E3 are highlighted, along with the main fate of the target 




Innate immunity represents the first line of defence employed by our immune system to fight against 
pathogenic microorganisms. Human primary cells express restriction factors to block the replication and 
spread of viruses. To react to this immune response, viruses have evolved in order to counteract this effect. 
One such strategy used by viruses is to hijack cellular proteasomal degradation pathways, including  UPS, 
to degrade the host restriction factors, so they can gain entry into target cells and replicate 33.  
In 1990, it was demonstrated that the E6 protein of the oncogenic human papillomavirus (HPV) 
promotes p53 degradation through the ubiquitin proteasome system 41. This was the first evidence 
supporting the ability of viruses to exploit the host immune system for their own purposes, in particular to 
utilize the UPS to interfere with the regulation of the cell cycle. Since then, it has become clear that members 
of almost all viral families subvert or exploit both the cellular Ub-conjugating and -deconjugating 
machineries in different phases of their replication cycle 33,42–46. 
 
1.5. EC5S Ubiquitin-ligase complex 
 
The largest E3 superfamily consists of multi-subunit 
Cullin-RING ligases (CRLs). CRLs are nucleated by an 
extended Cullin scaffold interacting with a catalytic RING-
containing protein, either RBX1 or RBX2. The Elongin B and 
C–Cullin–SOCS box protein (ECS) family also belongs to 
the Cullin RING ligase (CRL) superfamily. Elongin B and C 
complex (Elongin BC) is used as an adaptor in the ECS 
complex. In this family, the scaffold protein can either be 
Cullin 2 (Cul2) or Cullin 5 (Cul5). In the case of the systems 
using Cul5 protein it is named the EC5S Ubiquitin-ligase 
complex (Figure 1.4) 47,48.  
HIV-1 Vif protein is one example of a viral protein 
recruiting the EC5S Ubiquitin-ligase complex for its own 
purpose. Vif recruits a multi-subunit E3 Ub ligase complex 
composed of a scaffold protein, Cul5, RING-box protein, a 
SOCS box binding protein complex, Elongin BC, as well as 
the core binding factor beta (CBF-β) 42,49–55. Vif achieves this by direct binding to Cullin 5. The ultimate goal 
of Vif-CBF-β-ElonginB-ElonginC-Cullin5-Rbx E3 complex is to polyubiquitinate APOBEC3G (host 
restriction factor) leading to its proteasomal degradation. As a consequence, APOBEC3G is not 
incorporated into the viral particle and HIV-1 can replicate in de novo infected cells. It has to be mentioned 
that additional APOBEC molecules (i.e. APOBEC3DE/3F) have been characterized for their ability to restrict 
Vif-defective HIV-1. The underlying mechanism and molecular details behind the recruiting process of Vif 
is already well characterized through the recently solved crystal structure of Vif-CBF-β-ElonginB-ElonginC-
Cullin5 complex 49. 
There is another viral protein that recruits this complex. Apart from its main role of tethering viral 
episome to chromosome, LANA is also shown to physically interact with many host proteins and manipulate 
them, including the EC5S ubiquitin-ligase complex by interacting with Elongin BC and Cul5. This has been 
shown for kLANA where substrates such as NF-κB, p53 and VHL (von Hippel-Lindau) proteins are target 
for proteasomal degradation 43, as well for mLANA that was also demonstrated, targeting the transcription 
factor p65 (also known as nuclear factor NF-κB p65 subunit, involved in NF-κB heterodimer formation) for 







Figure 1.4- Schematic representation of 
EC5S Ubiquitin-ligases family. Cul5 is used as 
a scaffold protein. Note that the Rbx2 is used for 




Figure 1.5– Difference in the localization of the SOCS-box element between kLANA and mLANA proteins.  
 
Although kLANA and mLANA are homologues proteins that recruit the same Ubiquitin-ligase 
complex, the SOCS-box motif are differently arranged between them (Figure 1.5), and possibly might act 
with a different molecular mechanism and physical interactions with the EC5S Ubiquitin-complex. The well 
characterized SOCS-box motif in the kLANA protein is composed of an Elongin BC box and a Cullin box, 
which is spatially located at its amino and carboxyl termini. This motif is necessary for LANA interaction 
with the Cul5–Elongin BC complex, respectively 43. On the other hand, mLANA contains an unconventional 
SOCS-box-like motif, where the Elongin B and C box and Cullin box are spatially together 44. 
Molecular details of LANA (both human and murine homologs) recruiting the EC5S ubiquitin-ligase 
complex are unknown. One of the goals of the present study was to understand the mechanism behind the 
recruiting process.  
 
1.6. Ubiquitin specific protease 7 (USP7) 
 
Ubiquitination, like other post-translational modifications, is reversible. Reversal of ubiquitination, 
or deubiquitination, is carried out by deubiquitinating enzymes (DUBs), which belong to the metallo and 
cysteine families of proteases. By reversing the actions of ubiquitin ligases, DUBs offer a way to fine tune 
the effects of ubiquitination as a post-translational modification 56. 
Ubiquitin-specific protease 7 (USP7), also known as Herpesvirus-associated ubiquitin-specific 
protease (HAUSP), is a deubiquitinating enzyme found in all eukaryotes that catalyses the removal of 
ubiquitin from specific target proteins, preventing its degradation 57,58. USP7 was first discovered as a 
protein in complex with the herpes simplex virus protein ICP0, a viral E3 ligase (15), and was termed 
HAUSP for herpes-associated ubiquitin-specific protease, to cooperatively facilitate viral replication 59. 
Since then, further studies have shown that HAUSP can bind to various other substrates and is involved in 
the stress response pathway, epigenetic silencing, neurodegenerative disorders, and progression of 
infections by DNA viruses 60. USP7 is 1102 amino acid residues long (128.3 kDa). It contains an N-terminal 
TRAF/MATH domain (from residue 54 to 208), a catalytic domain also called USP domain (from residue 
214 to 521), and a 64 kDa C-terminal region with five Ub-like domains (Figure 1.6) 61. 
Tumour Necrosis Factor (TNF)-receptor associated factors (TRAF) are a family of proteins that 
were initially identified for their capability of interacting with and regulating different members of the TNF 
receptors family. TRAFs are characterized by a C-terminal region encompassing about 180 amino acids, 
forming a 7-8 anti-parallel (3-sheets fold (TRAF-C domain), which is preceded by a coiled coil in theTRAF-
N-terminal domain. Meprins, a family of extracellular metalloproteases, also contain a C-terminal domain 
with high sequence homology to the TRAF-C domain5 which is predicted to form a similar anti-parallel β-







Figure 1.6- Schematic representation of USP7. USP7 contains a TRAF substrate binding domain (brown), a catalytic 
domain (orange), and five Ub-like domains (rainbow). Adapted from 63. 
 
The only DUB/TRAF domain containing protein found in the human and mouse genomes is USP7. 
The crystal structure of USP7 revealed an eight anti-parallel β-sheet fold, very similar to the TRAF-C domain 
of TRAFs. The USP7 -TRAF domain (USP7-TRAF) has been implicated in substrate recognition 62. 
Previous studies shown that the TRAF domain directly interacts with the substrates of USP7 such 
as p53, vIRF4, UbE2E1 and MDM2 64–68. The N-terminal domain of USP7 (USP7-NTD) recognizes a 
sequence motif ((P/ A)XXS) found in its interaction partners.  
Another interesting interacting partner is LANA that has been shown to interact with USP7 through 
its TRAF domain 69. This interaction involves a short sequence (amino acids residue 971 to 986) within the 
C-terminal domain of LANA with strong similarities to the USP7 binding site of the Epstein-Barr virus (EBV) 
EBNA-1 protein. 
In response to genotoxic stress, USP7 binds and deubiquitylates p53 thereby protecting it from 
proteasome-mediated degradation 70. Previous studies on the EBNA1-USP7 interaction have shown that 
EBNA1 binds the USP7-NTD, which is distinct from the catalytic domain, p53 is also shown to interact with 
the same domain. EBNA1 and p53 bind the same pocket in this domain but EBNA1 does so with an affinity 
that is approximately 10-fold higher than that of p53. As a result, EBNA1 interferes with the binding and 
stabilization of p53 by USP7 and with p53-mediated apoptosis in response to DNA damage 66. The same 
authors also found that USP7 had a large stimulatory effect on the DNA-binding activity of EBNA1 in vitro 
and can form a ternary complex with DNA-bound EBNA1 71. 
This work reports the crystal structure of USP7-kLANA complex and also discusses the structural 
insights derived from this complex. Since EBV has a higher homology to KSHV, of the known human 






2. MATERIALS AND EXPERIMENTAL PROCEDURES 
2.1. Constructs Design 
 
To facilitate the structural studies and assays of kLANA interactions, several constructs were 
designed. For the interaction studies of kLANA with Elongin BC, three kLANA constructs (kLANA207-321, 
kLANA207-295 and kLANA188-295) were designed in the N-terminal domain of the protein. To design this 
constructs, was used the DisMeta server using the N-terminal domain, of kLANA sequence. DisMeta server, 
runs several programs simultaneously, including GlobPlot 72, ANCHOR 73, DISOPRED 74, among others, 
that mainly predicts disordered/unstructured regions and secondary structure elements. The two regions 
that were important to be incorporated in the constructs were the Elongin BC binding region (residues 210-
222) and a helix (residue 281-293) for structural stability. Figure 2.1 is a schematic illustration of all LANA 
constructs used in this work. All mLANA constructs were kindly provided by Dr Pedro Simas, Viral 
Pathogenesis Unit, IMM and the others kLANA constructs (kLANA51-321, kLANA4-333^929-1162 and kLANA4-
32^888-1162) were cloned by Dr. Rajesh Ponnusamy, Structural Virology Lab, ITQB. 
CBF-β was previously shown to be important for Elongin BC interaction with the Vif protein. 52,55. 
For the interaction studies of LANA with Elongin BC and CBF-β, three versions of CBF-β (only vary on 
sequence size) and one construct of the Elongin BC complex were used. Full length Vif was also used in 
the assays as a positive control.  
 
Figure 2.1- Schematic illustration of kLANA and mLANA constructs used in this study. The numbers 








For the interaction studies of kLANA with USP7 protein, the construct kLANA971-1150 (Figure 2.2) in 
the C-terminal of the protein that simply contains the USP7 binding region (residues 971-986) and the DNA 
binding domain. Regarding to USP7 constructs used, it contains the N-terminal tumour necrosis factor-
receptor associated factor (TRAF)-like domain (residues 53-208) of USP7, showed to interact specifically 
with C-terminal sequences of kLANA, p53 and EBNA1 65,66,69,75. The first one, was from residues 54-205 
and the second construct was simply to make the construct shorter, from residues 54-198, also illustrated 




Figure 2.2-Schematic illustration of the constructs used in this study. The numbers indicate the amino acid 
residue. 
 
2.2. Cloning and Transformation 
 
All constructs were cloned using the sequence and ligation independent cloning (SLIC) technique. 
This cloning strategy is based on the 3´-to-5´exonuclease activity of T4 DNA Polymerase. PCR products 
with complementary overhangs are created by incorporating appropriate extensions in the primers and 
treating them with T4 DNA polymerase. The annealing of the insert and the vector is made in the absence 
of ligase by simple mixing of the DNA fragments. More details about this technique are described elsewhere 
76,77. Figure 2.3 illustrates the procedure of SLIC. First, the vectors were linearized with the desired 
restriction enzymes. In most cases, digestion of 2 µg of the vector for 1h at 37C, in a 50 µl reaction was 
performed. Then, linearized vectors were analysed with 1% agarose (Carl Roth) gel electrophoresis with 
SYBR safe DNA gel stain (Invitrogen), run at 80 V for 45min, follow by gel purification using QIAquick Gel 
Extraction Kit from Qiagen. Linearized vectors were treated with Shrimp Alkaline Phosphatase (SAP) 
enzyme.  
Second, the insert is prepared by PCR using primers with 15-17-bp extensions (depending on the 
GC content) homologous to each end of the linearized vector. Primers were designed with Oligo Analyzer. 
All the primers used in this study were synthesized by SIGMA-ALDRICH. 
 






Step Temperature (°C) Time Cycles 
Initial Denaturation 98 30 sec 1 
Denaturation 98 












Figure 2.3- Schematic Illustration of the Sequence-Ligation-Independent Cloning (SLIC) technique  
 
The PCR reaction components were: 100 µl total volume, 1µl Phusion DNA polymerase, 20 µl of 5× 
Phusion HF buffer; 2 µl of 10 mM dNTPs; 50 ng of DNA template and 5 pmol of each primer. The PCR 
cycling parameters are listed in Table 2.1. For the SLIC Reaction, 40 ng of vector and 80 ng of Insert are 
mixed and incubated at room temperature for 10 min with T4 DNA polymerase and 1x NEB Buffer 2.1 in a 
10 µl solution.  All enzymes and reaction components described here are from New England Biolabs. 
Third, the reaction mixture is placed on ice for 10 min for single-strand annealing and then the DNA 
is transformed directly in DH5α, Escherichia coli competent cells. This mixture is incubated for 30 min on 
ice, and after heat shock at 42 °C for 45 sec, 900 µl of SOC medium was added to the mixture. The cells 
were grown in an incubator shaker, at 37ºC for 60 min at 180 rpm. The entire content of cell suspension is 
then plated onto a LB agar plate containing the appropriate antibiotics (50 µg/ml kanamycin, 50 µg/ml 
spectinomycin, 100 µg/ml Ampicillin and 34 µg/ml of chloramphenicol). The plates were then incubated at 
37 °C, overnight.  
Next day, 3 to 4 colonies from each construct were picked for colony PCR confirmation of each 
construct using GoTag DNA polymerase (Promega) and for inoculation in LB medium, with appropriate 
antibiotics for overnight culture of each clone for mini-prep. The DNA mini-prep was performed using the 
Minipreps DNA Purification Systems kit (Wizards Plus- Promega). Alternatively to PCR screening, 
confirmation was also done by restriction enzyme double digestion of 500 ng of DNA, in a 10 µl reaction at 
37 °C for 30 min, analyzed by agarose gel electrophoresis for confirming positive clones. All the cloned 
sequences were finally confirmed through DNA sequencing by GATC Biotech labs.  
2.3. USP7 chimeric protein 
 
To generate the kLANA-USP7 chimeric protein, the complementary DNA sequence of kLANA peptide 
(residues 975-982) was inserted into the sequence of the forward primer, after the complementary 
sequence of the vector for SLIC cloning (5´-vector Sequence----LANA-peptide ---- USP7 sequence-
3´).Then followed by the SLIC protocol described above. 
The specific sequences of primers, vectors and restriction enzymes used in this study, for each construct, 














SLIC Primers (Tm) 
kLANA971-
1150 









gatgacccacaacctggc-3´ (Tm=63 ºC)   
RW: 5’-
GGCACCAGAGCGAGCTCTGCGGCCGCT
TAttcccctggctgggttaatgg-3’ ( Tm=61 ºC)   
kLANA971-
1150 







gatgacccacaacctggc-3´ (Tm=63 ºC)   
RW:5’-
GGCACCAGAGCGAGCTCTGCGGCCGCT
TAttcccctggctgggttaatgg-3’ ( Tm=61 ºC)   
kLANA207-
321 










caaggtccctctacacta 3’ (Tm=58 °C) 
RW:5’-  
GGCACCAGAGCGAGCTCTGCGGCCGCT
TActtggatgcttcttctgcaatc 3´ (Tm=57 °C) 
kLANA207-
321 







caaggtccctctacacta 3’ (Tm=58 °C) 
RW:5’-  
GGCACCAGAGCGAGCTCTGCGGCCGCT
TActtggatgcttcttctgcaatc 3´ (Tm=57 °C)  
kLANA207-
295 





caaggtccctctacacta 3’ (Tm=58 °C) 
RW: 5´-
GGCACCAGAGCGAGCTCTGCGGCCGCT
TActtggatgcttcttctgcaatc 3´ (Tm=57 °C) 
kLANA207-
295 







caaggtccctctacacta 3’ (Tm=58 °C) 
RW: 5´-
GGCACCAGAGCGAGCTCTGCGGCCGCT
TActtggatgcttcttctgcaatc 3´ (Tm=57 °C) 
kLANA188-
295 






gactctttagctccgtctac-3´ (Tm=58 °C) 
RW: 5´-
GGCACCAGAGCGAGCTCTGCGGCCGCT
TActtggatgcttcttctgcaatc 3´ (Tm=57 °C) 
kLANA188-
295 







gactctttagctccgtctac-3´ (Tm=58 °C) 
RW: 5´-
GGCACCAGAGCGAGCTCTGCGGCCGCT
TActtggatgcttcttctgcaatc 3´ (Tm=57 °C) 
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tgttgtcttcttgcc-3´ (Tm=58 °C) 
Vif1-192 








ggcaggtgatg-3´  (Tm=61 °C)  
RW: 5´-
AGGTTAATTAAGCCTCGAGctagtgtccattcattgta
tggctcc-3´ (Tm=59 °C) 
USP7-
TRAF54-206 












































2.4. Small Scale Expressions and Pull down assay´s  
 
Sequence-verified clones were transformed into chemically competent BL21 Star (DE3) pRARE2 cells 
for protein expression. These cells have chloramphenicol resistance. Freshly grown colonies were used to 
inoculate 3 ml overnight cultures of ZY-0.8G medium. All overnight cultures were grown in 50 ml Falcon 
tubes, in an incubator shaker at 37 C and approximately 180 rpm. In the next day, this overnight culture 
was used to set up a small scale cultures in 5-7 ml ZYP-5052 auto induction medium with a 0.07 starting 
OD. The cells were grown at 37 C for 2h followed by 18 C overnight. All media were supplemented with 
the appropriated antibiotics; cells were then harvested by centrifugation at 5000 rpm, for 15 min at 4 C. 
Small scale expression trials are normally used to determine the best conditions to express a particular 
protein. It´s normally tested in different media, with different temperatures, different concentrations of 
inducing agent and incubation times. In most cases of the proteins used in this study, the procedure was 
already optimized, where auto induction medium turn out to be the best condition for expression.  
For pull down assays, a co-transformation of 2 or 3 vector constructs was required. When using more 
than 3 antibiotics, the concentration of each is reduced by half to enable cell growth. The protocol used for 
co-expression is the same as described above.  
For small scale expression trials, 2 ml of cells were pellet and resuspended in 1 ml of homemade 
BugBuster solution (25 mM Na/k Pi, 150 mM NaCl, 25% Sucrose, 5 mM MgCl2, 1% Triton-X, pH 8.5) for 
cell lysis, supplemented with 0.25 mg/ml of lysozyme and 5 unit/ml of Omicleave nuclease (Epicentre). The 
resuspended cells were incubated with agitation, for 30 min at 4 ºC and cell lysates were clarified by 
centrifugation a16000g for 15 min at 4 C.  
Depending on the construct in question, either Ni-NTA agarose beads (Qiagen) for His-tag proteins or 
Gluthathione agarose beads (Thermo Scientifics) for GST-tag proteins were used. For affinity purification, 
40 µl of beads was added to clarified lysates and incubated with agitation at 4 C. The beads slurry was 
previously washed 3 times with cold PBS. After 1h incubation the beads were washed 2 times with 1 ml of 
cold PBS. In the case of Ni-NTA agarose beads, the PBS was supplemented with 20 mM of imidazole. 
After the washing steps, the beads pellet was boiled at 95 C for 10 min in 50 µl of SDS sample loading 
buffer. The solution was centrifuged at maximum speed for 10 min, and then 10 µl loaded in a 15 % tricine-
SDS-PAGE gel 78 for electrophoresis analysis.  
For total cell lysate (TCL) analysis, 50 µl of culture pellet was resuspended in 45 µl of Tris-HCl pH 7.5, 
and 5 µl of 20% SDS, boiled at 95 C for 10 min and centrifuged at maximum speed for 10 min and 5 µl 
loaded in a tricine-SDS-PAGE gel. Protein expression was confirmed by western blot analysis 79 using the 
appropriate antibody. 
 
2.5. Large Scale Expressions and Purification 
 
All proteins were expressed in the same conditions as identified by small-scale trials: Cultures of ZY-
0.8G medium supplemented with the appropriate antibiotics were prepared with freshly grown colonies. 
The cells were grown overnight in an incubator shaker, 180 rpm at 37 C. ZYP-5052 auto-induction medium 
was freshly prepared and supplemented with the appropriated antibiotics. 500 ml of culture, with a starting 
OD of 0.07 was grown, in 2L Flasks, at 37 C for 2h follow by 18 C overnight in an incubator shaker with 
a cooling system. To harvest the cells, the culture was centrifuge at 8000 rpm for 20 min at 4 C. The cell 
pellets were withier used immediately, or frozen and store at -20 C.  
 
2.6. Purification of kLANA truncations  
 
The cell pellet of 1L culture (~13 g of dry pellet)  of the GST-tagged version of kLANA971-1150 was 
resuspended by vigorous stirring for 30 min at 4 C, in 150 ml of buffer A (25 mM Na/K Phosphate, 500 mM 
NaCl, 10 % (v/v) glycerol, pH 7.5) supplemented with 1 M NDSB, 1 mM DTT, 10 mM MgCl2, 0.25 mg/ml of 
lysozyme, 5 Units/ml of omicleave (epicentre) and one tablet of EDTA-free protease inhibitor cocktail 
(Roche). Cells were then lysed using a Branson 450D sonicator with 10% of amplitude, 30 sec of pulse on 
followed by 30 sec of pulse off, for 2-3 min. Cell lysates were clarified by centrifugation at 19000 rpm, for 
40 min at 4 C.  
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All the purification steps were performed using an ÄKTA Explorer 10 FPLC System at room temperature 
(GE Healthcare). Clarified lysates were applied to 2 x 5 ml GSTrapTM 4B columns (GE Healthcare), 
connected in tandem, using a peristaltic P-1 pump (GE Healthcare), at 4 C. Unbound proteins were 
washed with buffer A and the protein was eluted in buffer B (25 mM Na/K Phosphate, 500 mM NaCl, 10 % 
(v/v) glycerol, 20 mM Glutathione, pH 7.5), using a two steps gradient.  
The main fractions were pooled and applied to a 5 ml HiTrap Heparin HP columns (GE Healthcare); 
the column was washed in buffer C (25mM Na/K Phosphate, 200 mM NaCl, pH 7.5) and the protein eluted 
using a linear gradient in buffer D (25mM Na/K Phosphate, 2 M NaCl, pH 7.5). The main fraction peak, was 
pooled, concentrated and injected onto a Superdex 200 Increase 10/300 GL column (GE Healthcare) which 
was pre equilibrated with buffer E (25 mM Na/K Phosphate, 500 mM NaCl, 5% (v/v) glycerol, pH 7.0). Purity 
of the protein was monitored at all stages of the purification process using a 12% SDS-PAGE gel 
electrophoresis, run at 200 V for 50 min. All kLANA protein truncations were purified in a similar manner to 
kLANA971-1150. 
 
2.7. USP7-TRAF domain Purification  
 
The cell pellet of 1L culture of the His-tagged version of USP754-205 was resuspended in 150 ml of buffer 
F (25 mM Na/K Phosphate, 500 mM NaCl, 10 % (v/v) glycerol, 20 mM imidazole, pH 8.0), supplemented 
with 10 mM MgCl2, 0.25 mg/ml of lysozyme, 5 Units/ml of omicleave and one tablet of EDTA-free protease 
inhibitor cocktail and incubated for 30 min, at 4 ºC with constant agitation. Cells were lysed using a Z Basic 
cell disruptor (Constant Systems Ltd.). Cell lysates were clarified by centrifugation at 19000 rpm, for 40 min 
at 4 ºC. 
Clarified lysates were applied to two 5 ml HisTrap HP columns (GE Healthcare), with a peristaltic pump 
at 4 C. The columns were washed with buffer F and the protein was eluted using a linear gradient with 
buffer G (25 mM Na/K Phosphate, 500 mM NaCl, 500 mM imidazole, pH 7.5). The main fractions were 
pooled and 3C protease was added in a 1:100 molar ratio with an addition of 2 mM DTT and 1 mM EDTA. 
The protein was cleaved under agitation, overnight at 4 ºC. In the next day, to separate cleaved protein 
from uncleaved protein, the protein was passed through a 5 ml GSTrap HP column (GE Healthcare). Then, 
the protein was concentrated and injected into a HiLoadTM 16/600 SuperdexTM 75 pg column (GE 
Healthcare), which was pre equilibrated in buffer H (20 mM Tris-HCl, 100 mM NaCl, pH 7.5). Purity of the 
protein was monitored at all stages of the purification process using a 12% SDS-PAGE gel electrophoresis, 
run at 200 V for 50 min.  
All USP7 protein truncations were purified in a similar manner to USP754-205. 
 
2.8. Thermofluor experiments 
 
The fluorescence-based thermal shift assay or differential scanning fluorimetry (DSF) is a technique 
commonly use to access the optimal stabilizing buffer components to achieve high purification yields 80. It 
is also widely used to identify the potential buffers and additives necessary to crystallize proteins 81,82.  
The thermofluor experiment requires the presence of a fluorescent dye that will interact with exposed 
hydrophobic regions. It´s principle is based on the detection of changes in the exposure of a protein´s 
hydrophobic core upon heat denaturation. For many proteins the gradual increase of temperature has little 
effect on the protein fold, until a temperature is reached where it will quickly unfold. At this point, the 
unfolded protein will expose its hydrophobic core and the dye will become fluorescent. In an ideal case, it´s 
possible to draw a sigmoidal curve that allows the calculation of a melting temperature (Tm), which 
corresponds to the temperature where 50% of the protein is unfolded, and this allows the determination of 
the buffer more stable for a protein, by comparing the several melting temperatures of the protein in different 
buffers 80. 
Thermofluor experiments were performed with USP7 N-terminal TRAF domain, using the USP754-205 
truncation, to access the protein stability at different pH´s, and when incubated with three different peptides. 
The peptides used were: two from the N-terminal part of kLANA protein, k10 with the amino acid sequence: 
975DPQPGPSREY984 and k16 with the amino acid sequence: 971PDDDPQPGPSREYRYV986; the last 
peptide is from p53 protein with the amino acid sequence: 358EPGGSRAHSS367. There are several studies 
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about the interaction of USP7 with p53, so this protein will be used as a control in the experiment. All 
peptides were synthesized by SIGMA-ALDRICH. 
This USP7 protein is very soluble, which hampers the growth of protein crystals. With the goal of 
producing high-quality crystals, buffer screening was performed to find the optimal condition where the 
protein is less soluble, in a way that favours the formation of crystals. Protein was purified by Ni-NTA and 
the tag was cleaved using 3C protease followed by gel-filtration purification. The protein was in 10 mM Tris-
HCl, 100 mM NaCl, pH 7.5. 
For the thermofluor assay a real-time PCR Detection System iQ5TM (Bio-Rad) was used. The assay 
was performed using a 96-well thin-wall PCR plate (Bio-Rad). The total reaction volume was 20 µl and 
tested 24 different buffers for each sample, from the JBS Solubility kit (Jena Biosciences). The peptides 
were incubated with the protein in a 2:1 molar ratio, overnight at 4 C. The final amount of protein in the 
assay was 2.5 µg and a 5-fold (final concentration) of SYPRO Orange (Invitrogen) was used. For dilution 
buffer it was used 25mM HEPES pH 7.5.  
After pipetting of samples, the plates were sealed with optical quality sealing tape (Bio-Rad) and 
centrifuged at 4000 rpm for 1 min. For the thermofluor experiment the plates were heated from 20 C to 90 
C in increments of 1 C.  
From this experiment, six buffers were chosen in a pH range from 4.0 to 8.5, and another thermofluor 
assay was performed, following the protocol described above. Nonlinear regression analysis in the curve-
fitting program GraphPad Prism was used to construct melting curves and calculate Tm values for each 
sample condition. All experiments were carried out in triplicate. 
 
2.9. Electrophoretic Mobility Shift Assay  
 
The electrophoretic mobility shift assay (EMSA) is a commonly used method to identify DNA binding 
proteins. It is based on the fact that labelled DNA with bound protein migrates more slowly through a 
polyacrylamide gel than the corresponding protein-free DNA 83. In theory, an EMSA is very easy and simply 
to perform, but in reality a clean and successful gel shift requires the optimization of a number of 
parameters. Crucial parameters, include binding buffers (salt, glycerol concentration and pH), non-specific 
competitor DNA (it is important to titrate an amount of nonspecific DNA, to avoid  non-specific binding) and 
non-denaturing gel conditions 84. 
For this EMSA assay, the kLANA4-32^888-1162 and mLANA123-314 proteins were used, against USP754-205 
truncation. DNA probes for LANA EMSAs were generated by 5´-end fluorescein (Flc) labeling with and 
annealing to its complementary sequence. The Flc-DNA was synthesized by SIGMA-ALDRICH. The probes 
used were: 
kLBS1-2 (5´-TTTGACGCCGCCGGGGCCTGCGGCGCCTCCCGCCCGGGCATGGGGCCGC-3’) for 
kLANA and mLBS1-2 (5´- TATAATGGATCCGGCGCCATGCGCCCGCGCCTGGGGCGCCACGCGGCG-
3´) for mLANA, correspond to the LBS1-2 site of the terminal repeat (TR) DNA sequences of KSHV and 
MHV-68, respectively. 
The assays contained LANA and either USP7 or BSA (used as a negative control). LANA was 
incubated with USP7 or BSA at room temperature for 30 min, prior to adding the labelled DNA. For both 
USP7 and BSA, the protein concentration used was 40 µM. LANA concentration was titrated from 0.05 µM 
to 0.7 µM. 
Protein mixtures were incubated with 0.2 µM of DNA probe, at room temperature for 30 min, in the 
presence of 0.63 µg of PolydI-dC (SigmaAldrich), in binding buffer (20 mM Na/K phosphate, 300 mM 
potassium chloride, 10 mM magnesium chloride, 1 mM EDTA, 10 % (v/v) glycerol, 0.1 % (v/v) Tween-20).  
IEF sample buffer (50% (w/w) Glycerol, Bio-Rad) was added to incubations prior to loading on a 5% 
non-denaturing TBE-polyacrylamide gel. The gel was run in TBE buffer for 3 hour at 200 V at 4 C, and 







2.10. Crystallization and Structure determination  
 
X-ray crystallography is a high quality approach to obtain the three-dimensional structure of 
macromolecules with atomic resolution, providing essential information regarding the molecular mechanism 
underlying the function. It also provides powerful insights about the way two molecules interact with each 
other. This technique is possible through the crystallization of the protein(s) of interest. A crystal is an 
orderly three-dimensional array of molecules, held together by non-covalent interactions. In a very simply 
way, when X-ray interact with the crystal, most of the X-ray light will be scattered by the electrons in the 
molecule, giving rise to a diffraction pattern. Since the crystal is formed by the repetition of individual unit 
cells through its entire volume, displayed by symmetry operations, it can be treated as three-dimensional 
diffraction. From the diffraction pattern we can determine the structure 85,86.  
To determine a 3D structure of a protein by X-ray crystallography there are several steps involved, from 
cloning, expression and purification of the protein to the first attempt on crystallizing the protein, where  we 
use sparse matrix screens, which are in fact a collection of diverse conditions of buffers, precipitants and 
other additives to search for initial crystallization conditions; After identifying “initial hit” conditions, the 
second step is the crystal optimization; Once  diffraction-quality-crystals are produced, a X-ray diffraction 
data set is collected; The last step is the structure determination and refinement of the 3D model 85,87 
Co-crystallization screens of USP754-205 (29 mg/ml) and USP754-198 (26 mg/ml) with peptides k10 and 
k16, and crystallization screens of USP7-Chimera (29 mg/ml) were performed. USP754-205 and USP754-198 
were incubated with the peptides, in a 1:2 molar ratio, for 1h at 4 C. The crystallization screens were 
performed using a Cartesian MiniBee robot (Genomics Solutions), using two sparse matrix formulations 
from commercial screens (JCSG-plus and PACT-Premier) from molecular dimensions. The sitting-drop 
vapor-diffusion method was used, with three different drops size: 100 nl of protein mixed with equal volume 
of the reservoir screening solution, 100 nl of protein using the double of the volume of the reservoir 
screening solution and 200 nl of protein using half of the volume of the reservoir screening solution.  The 
crystallization drops were imaged regularly using Minstrel DT UV imager (Rigaku). 
For optimization, plates were set-up manually using the hanging-drop vapour-diffusion method. While 
the co-crystallizations of USP7 failed, for USP7-Chimera crystals grown to full size in two to three days, at 
20 C in two different conditions: 0.1 M Tris-HCl 7.5, 0.2 M calcium chloride and 9% (w/v) PEG 2000 MME 
(Crystals also grown in the same condition, in pH 7.0 and pH 7.5 and in 10% and 11% (w/v) of PEG) and 
0.1 M Tris-HCl pH 9.0, 0.2 M magnesium chloride and 14% (w/v) PEG 1500; For this last condition, crystals 
were further optimized by serial streak-seeding  in increasing precipitant concentrations. Crystals grown to 
an optimal size in 7 days. 
In another attempt, to co-crystallize USP7 with k10 and k16 peptides, USP7Chimera crystals were used 
as seeds for streak-seeding, in clear drops. After several attempts, USP754-198 co-crystallized with the k16 
peptide, as small needle shaped in 0.1M Tris-HCl pH 8.5, 0.2 M lithium sulphate and 26% (w/v) PEG 3350. 
Further optimization to produce diffraction-quality-crystals failed.  
For USP7-chimera crystals, several cryoprotectant solutions and different cryo-soaking techniques 
were tested; The optimal way of cryo-cool-down the crystals, was using a two-steps approach, where the 
crystal is first soak in half of the cryosolution concentration, and then transferred to the final cryosolution 
concentration; The best cryosolution found was the solution with an PEG concentration increase of 3% 
(w/v) and the addition of 30% (v/v) Ethylene Glycol.  
All diffraction datasets were collected at Diamond Light Source (Harwell campus, Oxford), in beamline 
I04. The data were indexed and integrated using iMOSFLM 88, then merged and converted with 
POINTLESS and scaled in SCALA 89. The structure was solved by molecular replacement using PHASER 
90, with the TRAF-like domain of USP7 (PDB ID: 2F1W) as a search model; Model building was performed 








3.1. LANA recruiting the EC5S Ubiquitin Complex  
3.1.1. Cloning 
To identify strategies that could result in detecting LANA interaction with the EC5S Ubiquitin complex 
components, a number of prokaryotic plasmid expression vectors were constructed and tested for LANA 
and it´s predicted EC5S interaction partners. 
LANA N-terminal constructs kLANA207-321, kLANA207-295 and kLANA188-295 were cloned into two vectors: 
pET47 b(+), which incorporates a 6xHis-tag and pET49 b(+) which has both a GST and 6xHis-tag. All 
constructs were kanamycin resistant, and included a 3C protease cleavage site after the tag, for protein tag 
removal. pET47 b(+) and pET49 b(+) vector maps are illustrated in Figure S1A and S1B, respectively. For 
SLIC cloning, both vectors were digested with BamHI and NotI restriction enzymes, and then treated with 
SAP to prevent relegation. To confirm complete digestion and purification, the linear vectors were run on a 
1 % agarose gel (Figure 3.1a).  
 
Figure 3.1- Cloning steps of kLANA constructs. (a) Linearization of vectors using BamHI and NotI restriction 
enzymes; lane 2: pET47 b(+) (5203 bp) and lane 3: pET49 b(+) (5926 bp); b) PCR amplification of inserts with the 
specific SLIC primers; lane 2: kLANA207-321 (345 bp); lane 3: kLANA207-295 (267 bp); lane 4: kLANA188-295 (324 bp); (c) 
Clone validation by PCR using GoTaq. 
 
Inserts were amplified by PCR (Figure 3.1b) with gene specific primers containing 10-15 bp of 
overlapping sequence from either the BamHI or NotI-cleaved vector end. Vectors and inserts were then 
mixed and treated with T4 DNA polymerase. After transformation, colony PCR was performed to identify 
positive clones. Figure 3.1c illustrates the positive colonies from the colony PCR as analysed by 1% 
agarose gel that show the presence of all inserts, except in the case of kLANA207-321 construct cloned into 
pET-47 b(+). For this case, the SLIC reaction was successfully repeated (Figure 3.1d). All positive were 





The strategy planned to study the interaction between LANA and its ubiquitin ligase partners involves 
co-expression of genes and protein pull-down assays to confirm binding activity. The easiest approach for 
co-expression of multiple genes in the same E. coli host is to use vectors with different resistance markers, 
each vector bearing a single gene 93. Thereby, the cloning of kLANA, CBF-β as well the experimental control 
protein, Vif, was carefully planned to allow for co-expression in compatible vectors. 
 
Figure 3.2- Cloning steps of CBF-β and Vif constructs. (a) Vector linearization and PCR amplification of CBF- β 
truncations. Lane2: pNEATH (5763 bp) linearization with NdeI and BamHI restriction enzymes; Lane 3: PCR 
amplification of CBF-β160 (507 bp); Lane 4: PCR amplification of CBF-β170 (546 bp); Lane 5: PCR amplification of CBF-
β182 (582 bp); b) CBF-β clone validation by restriction digestion; c) Vector linearization and PCR amplification of Vif. 
Lane 2: PCR amplification of Vif (579 bp); Lane 3: pET-47b(+)(5203 bp) linearization with BamHI and XhoI restriction 
enzymes. d) Vif clone validation by restriction digestion. 
 
kLANA truncations were cloned into pET vectors, (kanamycin resistant) and Elongin BC was 
already cloned, by a member of the lab, into pCDF-Duet (spectinomycin resistance). For CBF-β truncations, 
(CBF-β1-160, CBF-β1-170 and CBF-β1-182) the pNEATH vector was chosen and has ampicillin resistance, 
allowing the co-transformation of the three plasmids. pNEATH vector also includes a 6xHis-tag (Vector map 
illustrate in Figure S1C). 
CBF-β cloning was performed in a similar way to kLANA constructs, where first the pNEATH vector 
was linearized with NdeI and BamHI restriction enzymes (Figure 3.2a). Clone validation was performed by 
restriction enzyme digestion (Figure 3.2b). 
The Vif protein was used as a control experiment to validate the pull down assays performed with 
LANA truncations, as it has been previously shown to interact with Elongin BC and CBF- β 49,53–55; Vif was 
cloned in the same vector as kLANA truncations, pET 47 b(+), using BamHI and XhoI as restriction 
enzymes. Figure 3.2c and d show Vif cloning steps. Both CBF-β and Vif constructs were successfully 
cloned. 
 
3.1.2. Expression of kLANA N-terminal domain truncations 
 As a starting point of the study, expressions tests were performed, focusing only on the 
soluble fractions to evaluate the expression of the genes and also to access the purification ability with 
affinity beads in these constructs.  
 Three different media were tested: LB, TB and ZYP-5052 auto-induction medium. The GST 
version of kLANA (cloned into pET 49 b(+) vector) and the corresponding glutathione agarose beads were 
used. Figure 3.3a, b and c show the purification results in Tricine gels for GST- kLANA207-321, GST- 









Figure 3.3- Expression test of kLANA N-terminal truncations. Small scale expressions of GST-kLANA in three 
different mediums were prepared; the cells were lysed using a BugBuster solution, and GST-agarose beads were 
added to clarified lysates. (a), (b), (c) resulting fractions from pull down of GST- kLANA207-321 (38 kDa), GST- kLANA207-
295 (35 kDa) and GST- kLANA188--295 (37 kDa), respectively, were run on a 12% Tricine SDS-PAGE gel and stained with 
Coomassie blue. (d) Further confirmation of the proteins was performed by immunoblotting using α-M2 antibody that 
recognizes the DYKDDDDK peptide, present on the GST tag. Arrows indicate the expressed proteins. TCL- Total cell 
Lysate, FT- Flow through from beads purification, W-Wash of unbound proteins, GST- Beads purification. 
 
All genes were expressed, in each medium; the proteins were also successfully purified by the 
affinity agarose beads, of which 2xLB medium contained less contaminants. Hence, purified fractions from 
2xLB medium was used for immunoblotting assay (Figure 3.3d); although there is a lot of unspecific binding 
of the antibody to other proteins, it was possible to confirm the presence of three kLANA truncations, 
indicated by the box, through its different molecular weights. 
3.1.3. CBF-β does not bind to N-terminal kLANA truncations 
The core-binding factor subunit beta, CBF-β, is a host protein required for preserving HIV-1 
infectivity 52. It is hijacked by HIV-1 Vif to form the Vif-CBF-β-CUL5-ELOBC complex, for Vif-mediated 
degradation of APOBEC3G 49,52,55. It is possible that LANA may recruit CUL5-EloBC, similar to HIV-1 Vif 
protein, by interacting with CBF-β. Since HIV-1 Vif has a similar function to LANA, a simple pull down 
experiment was performed in order to investigate the possible interaction between LANA and CBF-β. 
His-CBF-β was co-transformed and expressed with GST-His-kLANA. , Glutathione agarose beads 
were used to bind GST-His-LANA for pull down experiments. Ni-NTA agarose beads were used to identify 
the expression of LANA and CBF-β (Figure 3.4). As another control, CBF-β1-170 was expressed alone and 








Figure 3.4- CBF-β do not interact directly with kLANA N-terminal truncations. Co- expressions of GST-kLANA 
with CBF-β were performed. The cells were lysed using a BugBuster solution, and GST-agarose beads were added to 
clarified lysates. (a) GST- kLANA207-321 (38 kDa) assay with three CBF-β truncations: His-CBF-β1-160 (19 kDa), His-
CBF-β1-170 (21 kDa) and His-CBF-β1-182 (22 kDa); the resulting fractions from pull down of GST- kLANA207-321, were run 
on a 12% Tricine SDS-PAGE gel and stained with Coomassie blue. Both proteins were possible to be identified in the 
gel, i.e. they were expressed, but LANA was not able to pull down CBF- β. The same result was obtained with the other 
two constructs of LANA, (b) GST- kLANA207-295 (35 kDa) and GST- kLANA188-295 (37 kDa). Arrows indicate the 
localization of CBF-β truncations and the boxes the localization of LANA truncations. FT- Flow through from beads 
purification, W-Wash of unbound proteins, GST agarose beads purification, Ni-NTA agarose beads purification. 
 
As a first trial, kLANA207-321 was used to perform the assay with all CBF-β truncations (Figure 3.4a). 
In Figure 3.4a lanes 3, 8 and 13 it is possible to identify kLANA207-321 and CBF-β from the Ni-NTA agarose 
beads pull down, indicating that both proteins were expressed. For the GST-pull down the same result does 
not occur. From lanes 4, 9 and 14, kLANA207-321 was clearly bound to the beads, but CBF-β was not. The 
second assay (Figure 3.4b) was performed using two other N-terminal kLANA truncations, co-expressed 
along with CBF-β1-170. The same conditions from the previous assay were used, and similar results were 
obtained. Again, both proteins (kLANA and CBF-β) are identified in the Ni- purification, (Figure 3.4b, lanes 
4 and 8) but not in the (GST-pull down, Figure 3.4b, lanes 5 and 9).   
These assays were repeated, with all possible combinations between LANA and CBF-β 
truncations, and similar results were obtained.  
 
3.1.4. kLANA does not bind to CBF-β and Elongin BC complex  
Without positive results from pull down assays of kLANA with CBF-β, Elongin BC co-expression was 
added to the expression trials. The rationale being that CBF-β may only interact with LANA in the presence 
of other Ubiquitin complex components, like the adaptor Elongin BC, already shown to interact with the N-




Figure 3.5- N-Terminal kLANA truncations do not interact directly with CBF-β neither with Elongin BC proteins. 
GST-kLANA truncations were co-expressed with His-CBF-β1-170 (21 kDa) and Elongin-B (13 kDa) and Elongin C (11 
kDa). The cells were lysed using a BugBuster solution, and GST-agarose beads were added to clarified lysates. (a) 
GST- kLANA207-321 (38 kDa), GST- kLANA207-295 (35 kDa), GST- kLANA188-295 (37 kDa) fractions from the beads 
purification were run on a 12 % Tricine SDS-PAGE gel, and (b) the panel represents the immunoblotting of the same 
samples. The LANA truncations are the only samples which had a GST-tag and they were successfully bound to the 
glutathione beads.  TCL- total cell lysate, W-Wash of unbound proteins, GST- GST agarose beads purification. 
The four proteins, LANA, CBF-β and Elongin BC were co-expressed, of which LANA is the only 
component of the complex that has a GST tag. The samples from the pull down assays were run on a SDS-
gel (Figure 3.5a), and the same samples were used for Immunoblotting assays (Figure 3.5b); His-probe 
was used to reveal LANA and CBF-β proteins, and specific antibodies to reveal the Elongin BC proteins. 
Assays were performed in the same manner for all three kLANA truncations.  
All four proteins, LANA, CBF-β and Elongin BC were expressed (Figure 3.5b, lanes 1, 3 and 5), but 
only kLANA protein was purified and neither CBF-β nor Elongin BC was pull down (Figure 3.5b, lanes 2, 4 








3.1.5. mLANA interacts with Elongin BC 
The well characterized SOCS-box motif in the kLANA protein is composed of an Elongin BC box 
and a Cullin box, which is spatially located at its amino and carboxyl termini. This motif is necessary for 
LANA interaction with the Cul5–Elongin BC complex, respectively 43. 
 
Figure 3.6- Elongin BC proteins interact directly with mLANA truncations. His-mLANA truncations were co-
expressed with CBF-β1-170 (21 kDa), Elongin B (13 kDa) and Elongin C (11 kDa). The cells were lysed using a cell lysis 
solution, and Ni-NTA-agarose beads were added to the clarified lysates. (a) His-mLANA39-314 (30 kDa), His- mLANA88-
314 (25 kDa), His- mLANA104-314 (23 kDa), GST-His-kLANA4-333^929-1162 (87 kDa) fractions from the beads purification 
were run on a 12 % Tricine SDS-PAGE gel, and (b) western blot representing the immunoblotting of the same samples. 
The LANA truncations and CBF-β are His-tagged and Elongin BC is not tagged. Elongin B was pull down with mLANA 
truncations. FT- Flow through from beads purification, W-Wash of unbound of proteins, Ni- Ni-NTA agarose beads 
purification. 
 
On the other hand, the latency-associated protein ORF73 (mLANA) has an unconventional SOCS-
box-like motif, where the Elongin B and C box and Cullin box are spatially together. It was also shown that 
mLANA assembles in an ElonginC/Cullin5/SOCS (suppressors of cytokine signalling)-like complex, 44 to 
inhibit the transcriptional activity of the host nuclear factor-kappa B (NF-kB).  
25 
 
Therefore, it will be interesting to compare the interaction of Elongin BC between kLANA and 
mLANA proteins. It was also decided to investigate the potential contribution of the C-terminal domain of 
kLANA in the interaction with CBF-β and Elongin BC, using kLANA4-333^929-1162 truncation (From residue 1 
to 333 with a deletion between N-terminal and C-terminal domain and from 929 to 1162 residue) that 
contains a deletion between the N- and C- terminal domains, but contains the Elongin BC and Cullin5 
boxes.  
 Pull downs assays were performed using mLANA39-314, mLANA88-314, mLANA104-314 and kLANA1-
333^929-1162 truncations, all containing the SOCS-box-like motif. mLANA truncations are cloned into pET 47 b 
(+), including a His-tag and kLANA4-333^929-1162 cloned into pET 49 b (+) , which includes a GST and His-tag.  
The pull-down assays were repeated as before. mLANA truncations, and kLANA4-333^929-1162  were 
co-transformed with CBF-β and Elongin BC. Since mLANA truncations are His-tagged, the pull down were 
performed using Ni-NTA beads, which means that His-CBF-β will also be pull down. Samples were run on 
a 12% SDS-gel (Figure 3.6a), and proteins were further confirmed by immunoblotting (Figure 3.6b). 
The experiment successfully purified the three mLANA constructs, and Elongin B successfully 
interacted in the pull-down assay (Figure 3.6b, lanes 3, 6 and 9); Although, Elongin C has been shown to 
directly bind to BC-box, it does not appear in the blot, or in the Elongin C control experiment. It is likely that 
Elongin C antibody has lost its activity and we will assume that Elongin C was also pulled down since 
Elongin B was present.  
The same did not happen for kLANA4-333^929-1162 truncation (Figure 3.6b, lane 13). The protein was not 
bound to the beads, which indicates that probably the protein was not expressed. 
 
3.1.6. Vif interacts with Elongin BC 
Characterization of the interaction of full-length HIV-1 Vif protein with CBF-β and Elongin BC 
proteins is already well studied 49,51–54. A similar approach was used in this study to define the interaction 
between Vif and CBF-β 55. In order to validate the experimental protocol used in LANA pull downs, the 
same assay was performed with Vif protein (Figure 3.7). The four proteins were expressed and as expected, 
Vif was able pull down Elongin BC (Figure 3.7a), validating the protocol being used.  
 
Figure 3.7- Vif interacts directly with Elongin BC. Control experiment, with Vif protein for validation of LANA pull 
down assays. His-tagged Vif was co-expressed with CBF-β and Elongin BC. The cells were lysed using a cell lysis 
solution, and Ni-NTA-agarose beads were added to clarified lysates. (a) the fractions from the beads purification were 
run on a 12 % Tricine SDS-PAGE gel, and on (b) is represented the immunoblotting of the same samples. Vif (23 kDa) 
and CBF-β1-170 (21 kDa) are His-tagged while Elongin B (13 kDa) and Elongin C (11 kDa) are not tagged. All proteins 
were expressed and Elongin BC was pull down along with Vif. TCL- Total cell lysate, FT- Flow through from beads 
purification, Ni-NTA agarose beads purification. 
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3.2. Binding activity of LANA to USP7 
3.2.1. Cloning, Expression and Purification 
To facilitate structural studies, a new kLANA construct was designed in the C-terminal domain, and 
designated kLANA971-1150 (from 971 to 1150 residue). This construct contains the USP7 binding region and 
was designed for the characterization of LANA interaction with USP7. For these studies the USP754-205 
truncation was used and two more USP7 constructs were designed and cloned. The first construct (USP754-
198) was a shorter version of USP754-205 truncation for use in crystallizing the USP7-kLANA complex and the 
second truncation (USP7chimera) was designed to create a fusion version of USP7-kLANA complex, i.e. 
USP7 gene followed by insertion of kLANA gene (8 aa residues), where both proteins are encoded from a 
single continuous DNA gene sequence. This construct was also created for crystallization purposes.  
 
Figure 3.8- Cloning steps of kLANA971-1150 and USP7 constructs. (a) Vectors linearization with BamHI and NotI 
restriction enzymes and PCR amplification of kLANA971-1150; lane2: PCR amplification of kLANA971-1150 (540 bp); lane 
3: restriction digestion of pET47 b(+) (5203 bp); lane 4: restriction digestion of pET49 b(+) (5926 bp). (b ) kLANA971-1150 
clone validation by single restriction digestion. (c) Vectors linearization for USP7 cloning: lane 2: pET47 b(+) digestion 
with BamHI and XhoI restriction enzymes; lane 3: pNEATH (5763 bp ) digestion with NdeI and BamHI restriction 
enzymes. (d) USP7 clone validation by restriction digestion. 
 
kLANA971-1150 and USP7 truncations, were cloned in a similar way to kLANA. kLANA971-1150 was 
also cloned into pET 47 b(+) and pET 49 b(+), using BamHI and NotI restriction enzymes (Figure 3.8a). 
Clone validation was performed by single restriction digestion (Figure 3.8b). USP7Chimera was cloned into 
pET 47 b(+), between BamHI and XhoI restriction sites and USP754-198 was cloned into pNEATH, between 
BamHI and NdeI restriction sites (Figure 3.8c). For both cases, inserts were confirmed by digestion, using 
the respective restriction enzymes (Figure 3.8d). Both kLANA971-1150 and USP7 truncations were expressed 
successfully. However, kLANA971-1150 turned out to be a very unstable protein, even in higher salt 
concentrations and it was only possible to purify the GST version without cleaving the tag.  
On the other hand, all USP7 truncation behave very stably and they were very soluble proteins. 
During purification of these proteins, we saw immediately different behaviour between the three USP7 
truncations. While USP754-205 and USP754-198 truncations behave as monomer, USP7 chimera behaves as 
dimer (Figure 3.9) giving already one indication of the interaction between USP7 and the LANA peptide in 
which it is interacting in “trans”, that is USP7 fused with C-terminal LANA peptide is interacting with another 




Figure 3.9- Size exclusion analysis of USP7 truncations. The USP7 truncations were loaded into a HiLoad 16/600 
Superdex 75 pg column and the elution profiles were analysed. USP754-205 and USP754-198 behave as monomer while 
USP7Chimera behaves as a dimer.  
 
3.2.2. Effect of USP7 on DNA binding by LANA 
USP7 was previously reported to interact with herpes viral proteins such as, HSV-1 ICP0 59 and EBV 
EBNA-1 94, and to be important for the life cycle of both viruses. USP7 was also shown to have stimulated 
the DNA binding activity of EBNA-1.  
 
 
Figure 3.10- Analysis of USP7 effect on LANA’s DNA binding activity. EMSAs showing titrations of LANA with 0.2 
µM of DNA recognition site, in the presence of 40 µM of USP7 or in the presence of 40 µM of BSA as a negative control. 
a) Complexes of kLANA4-32^888-1162 with kLBS1-2 and b) Complexes of mLANA124-314 with mLBS1-2. The 5% acrylamide 




Recently, USP7 was shown to interact with both kLANA and mLANA. Similar to EBNA-1, a motif region 
in kLANA preceding the DNA binding site has been mapped for USP7 binding site. However, a similar motif 
was absent in mLANA but has still been shown to interact with USP7 69. Since LANA is a functional 
homologue of EBNA-1, we investigated whether USP7 could also have an effect on DNA binding activity 
of both kLANA and mLANA 71. 
To assess the effect of USP7 on the DNA binding activity of LANA, an electrophoretic mobility shift 
assay (EMSA) was performed with a kLANA truncation that contains both N-terminal and C-terminal 
domains (kLANA4-32^888-1162) and includes the USP7 binding site. For mLANA, a C-terminal domain 
(mLANA124-314) was used for the EMSA. Purified kLANA and mLANA was incubated with Fluorescein 
labelled-DNA (Flc-DNA) containing two LANA binding sites (LBS 1-2 (high and low affinity site) from the TR 
element of the viral episome DNA); kLBS1-2 or mLBS1-2, respectively, in the presence of excess USP7 or 
in the presence of the same quantity of BSA (as a negative control). 
Repeated experiments consistently showed no stimulation for both kLANA and mLANA’s DNA 
binding activity by USP7, different from the homologous EBNA1 protein (Figure 3.10a and b). The fact that 
USP7 enhances the DNA binding in the case of EBNA-1, but not in kLANA and mLANA could indicate a 
different binding mechanism of USP7 or DNA, between LANA and EBNA1proteins. 
 
3.2.3. Thermofluor 
For thermofluor experiments, USP754-205 truncation (USP7-TRAF) was initially screened in 24 different 
buffers, among which six were chosen and incubated with two kLANA peptides (k10 and k16) and p53 
peptide. The experiment was performed in six different buffers, keeping the buffer concentration (100 mM) 
constant. For data analyses, the melting temperature of each sample in each buffer was calculated, Figure 
3.1 and the corresponding melting curves are represented in supplementary information, figure S2. 
 
Figure 3.11- Melting temperatures of USP7-TRAF alone and incubated with three peptides. Melting temperatures 
of USP7 incubated with three peptides. Midpoint temperatures of the protein-unfolding transition (Tm) were calculated 
for US7-TRAF and incubated with three peptides, k10, k16 and p53 in the presence of six buffers. 
 
To identify a ligand or a buffer condition that stabilizes a protein, the Tm value of the protein under 
each condition of the screen needs to be compared with the reference Tm. 
The Tm values measured in buffer were subtracted from the Tm values for the control experiments, and the 
change in unfolding temperature, ΔTm, was calculated (Figure 3.12).  
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A positive ΔTm can be associated with an increase in structural order and a reduced conformational 
flexibility, whereas a decrease in stability, negative ΔTm, indicates either the buffer induces protein structural 
changes to a disordered conformation, or it can be a sign of misfolding.  
 
 
Figure 3.12- Assessment of buffer stabilizing effect through thermofluor analysis. The Tm value of each condition 
were compared to reference Tm. Changes in the unfolding temperature (ΔTm) were calculated for measurements in five 
buffers for four different protein samples. The histogram represents the median ΔTm values and error bars the standard 
deviation. A negative median ΔTm value signifies that the buffer destabilizes the protein and a positive ΔTm value 
indicates that the buffer has a stabilizing effect. Buffers with lower pH (4.5, 5.5 and 6.5) have a more stabilizing effect 
compare to buffers with a higher pH (7.5 and 8.5). 
 
Obviously for most proteins, the goal of thermofluor experiment is to identify an increased melting 
temperature in order to obtain a protein sample with higher stability and hopefully homogeneity. However, 
the goal of this particular experiment was to look for the opposite effect: identifying a buffer system which 
will destabilize the protein. In such a buffer system, protein solubility would be decreased and consequently 
the chance of crystallization may be enhanced. Of note: USP7 solubility is very high, up to 100 mg/ml 
(reference buffer: 25mM HEPES, pH 7.5), hence we needed a higher quantity of peptide. 
For all USP7 samples, sodium acetate pH 4.5, sodium citrate pH 5.5 and Bis-Tris Propane pH 6.5 
buffers were stabilizing, whereas HEPES pH 7.5 and Tris-HCl pH 8.5 buffers significantly destabilize the 
protein. In other words, protein solubility decreased at higher pHs.  
If the ligand binds, the protein-ligand complex denatures at a higher temperature than the protein 
alone. The difference in the Tm value between the presence and absence of ligand reflects the binding 
ability.  
The Tm values measured in each buffer for USP7-ligand were subtracted to the Tm values for USP7-
TRAF alone, for each buffer and the change in unfolding temperature, ΔTm, was calculated (Figure 3.13). 
A positive ΔTm can be associated to a more stabilizing ligand and a negative ΔTm, indicates the opposite.  
A positive thermal shift is associated with a stabilizing effect and also with a higher binding affinity, 
meaning that k16 peptide seems to be the most stabilizing ligand for the protein and also the one with the 
higher affinity between the three tested ligands. In summary, k16 peptide has a higher affinity than the k10 
peptide and in turn, the k10 peptide has a higher affinity than p53. These results are in agreement with 





Figure 3.13- Characterization of the effect of peptides on the protein stability. Each histogram indicates the 
thermal shift of a peptide from the melting temperature of USP754-205 (without ligand), in each buffer. All experiments 
were done in triplicate and standard deviation represented with error bars. A positive median ΔTm value signifies that 
the peptide stabilizes the protein and a negative ΔTm value indicates that the peptide has a less stabilizing effect. The 
k16 peptide is the more stabilizing peptide, while the p53 peptide is the less one. 
 
3.2.4. Crystallization and X-ray structure 
3.2.4.1. USP7 co-crystallization with kLANA 
Initial attempts to co-crystallized USP7 with LANA were performed by using the USP754-205 
truncation incubated with k10 and k16 peptide. Several screening conditions were tested: with different 
protein concentrations, different molar ratios between USP7 and the peptide and different temperatures. 
Despite all these efforts, diffraction quality crystals were not able to be obtained.  
At this point a new strategy was designed. By analyzing previous conditions of crystal growth of 
USP7 N-terminal TRAF-like domain and also its structure and crystal packing from previous studies from 
Saridakis group, we observed that the region from residue 198 to residue 206 was involved in the crystal 
packing (Figure 3.14) in all of their crystal structures. Interestingly, seeds of USP7-bound with p53 crystal, 
had to be used for all their USP7 complex crystals. 95.  
Since USP754-205 construct failed to form quality crystals, USP754-198 truncation construct was 
created to obtain USP7LANA complex with different packing from Saridakis’s crystals. 
 New screens were performed with USP754-198 incubated with both kLANA peptides (k10 and k16). 
Micro-crystals of USP754-198-k16 were grown in 28 % of PEG 3350, 100mM Tris-HCl pH 8.5 and 0.2M 
Lithium sulfate. Further optimization by streak seeding was performed but was unsuccessful. This USP754-
198 construct also failed in getting quality crystals, so another completely different strategy was designed to 




Figure 3.14- Crystal packing of the USP7 N-teminal TRAF-like Domain. The residues 199 to 205 are coloured in 
red, showing the deleted region on USP754-198 truncation. Adapted from 95 , PDB code: 1YY6. 
 
3.2.4.2. Crystallization of the USP7-k10 chimeric protein  
There are several published X-ray structures of USP7 N-terminal TRAF-like domain bound to 
ligands, but most of them are from Saridakis’s group, who have used the same seed to obtain crystals of 
different USP7 complexes 64. However, crystals of USP7 with p53 and MDM2 ligands were obtained using 
chimeric proteins; that is, p53 and MDM2 peptide sequences were fused to the C-terminal region of USP7. 
Based on this strategy, the 975PQPGPSRE982 aa residues from LANA sequence were fused to the C-
terminal of USP7 to create USP7 chimeric protein.  
The chimeric protein was purified in 20mM Tris-HCl pH 8.0, 100mM NaCl buffer. This buffer choice 
was based on the previous thermofluor assays (Figure 3.12), where it was shown as a buffer with lower Tm 
to reduce protein solubility. In order to maintain protein stability, this buffer condition was only used in the 
last step of purification.  
 






In agreement with thermofluor data (Figure 3.12), the crystals were grown in higher pH buffers, 
which are destabilizing buffers, i.e. buffers were the protein solubility decreased (HEPES pH7.5 and Tris 
pH 8.5). The crystals were grown in PEG 2000 MME, 100 mM Tris-HCl and 0.2M CaCl2. The crystals had 
different shapes and growth times depending on both the PEG concentration and pH used (Figure 3.16).  
Small crystals were also obtained in PEG 1500, 100 mM Tris-HCl pH 9.0 and 0.2M MgCl2. To 
improve crystal growth in this condition, serial streak-seeding was performed in clear drops, using small 
crystals as seed in increasing precipitant concentrations (Figure 3.16). 
 
Figure 3.16- Crystal optimization by streak-seeding. Small crystals of USP7-k10 chimeric protein grown in 14% 
PEG 1500, 100mM Tris-HCl pH 9.0 and 0.2M of magnesium chloride were optimized by streak seeding. In seven 
days diffraction-quality crystals were obtained. 
 
In crystallization, another important parameter is to determine the best cryosolution and the best 
technique to cryocool down crystals. There are two relevant considerations to take into account: vitrification 
of the drop and the interaction between the cryo-solute and the protein inside the crystal. Crystals immersed 
in various cryoprotectants often develop cracks, bends, etc. indicative of stress by cryo solution to the 
crystal packing. Even small variations can be detrimental to crystal health and diffraction quality. This 
unwanted stress can be related to the different density/osmolarity between the crystal and the solution in 
which it is placed. Sucrose, glycerol and ethylene glycol are normally the most common cryo-agents that 
crystals like (i.e. survives in)96.  
 
Figure 3.17- Cryo cool down test of USP7chimera crystals. Two different cryo-agents were tested in two different 
approaches. Cryo soluition glycerol in the top panel and ethylene glycol in the bottom panel were tested in (a) one-step 
approach and (b) two-step approach.  
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These three cryo-agents were tested, and the best cryo-agent based on the external appearance 
was ethylene glycol. In order to maintain crystal quality we had to cryo-soak in a two-step approach. When 
transferring the crystals to the cryo-solution they instantly cracked (Figure 3.17a); however, if we first soak 
them in a solution with half of the final concentration, where they stayed stable, and then transfer them to 
the final cryo-solution the crystals survived (Figure 3.17b). 
 
3.2.4.3. X-ray structure of USP7-kLANA chimera 
To gain insight into the molecular basis of LANA interaction with USP7, the USP7chimera crystallized 
in 9% PEG 2000 MME, 100 mM Tris-HCl pH 8.0, 0.2M CaCl2 turn out to be the highest resolution data and 
the structure was determined using molecular replacement (Figure 3.19a). 
The model was refined to 1.9 Å of resolution (see Table 3.1 for structure solution and refinement 
statistics).The kLANA peptide was located in the F0-Fc difference electron density map. From residues 975 
to 980 the map showed excellent density, which allowed clear building of the kLANA peptide (Figure 3.18). 
For residues 981 and 982 the density map was less well defined, but adequate to allow theses residues to 
be built.  
 
Table 3.1- X-ray data collection and refinement statistics.  
 
Like all TRAF domains, the overall structure of USP7-TRAF forms an eight-stranded antiparallel β-
sandwich, with strands β1, β5, β6 and β8 in one sheet and strands β2, β3, β4 and β7 in the other (Figure 
3.19a). The interactions between LANA and USP7 mainly occur in the β7 strand (Figure 3.19b), similar to 









Values in parentheses are for the highest 
resolution shell. 
 
1 Rmerge =∑hkl∑i│I(hkl)i – 〈I(hkl) 〉│∕∑hkl∑i I (hkl)i, 
2 Rpim =∑hkl √
𝟏
𝒏
− 𝟏∑i│I (hkl)i – 〈I (hkl) 〉/ ∑hkl∑i 
I(hkl)i , where I(hkl) is the intensity of  reflection 
hkl and 〈I(hkl)〉 is the average intensity over all 
equivalent reflections. 
 
3 Rcryst =∑hkl│Fo (hkl) – Fc (hkl)│/ ∑hkl Fo (hkl). 
Rfree was calculated for a test set of reflections 
(5%) omitted from the refinement. 
Wavelength (Å) 0.98 
Space group P 21 21 21 
Cell dimensions: a, b, c (Å) 49.3, 61.1, 61.8 
α, β, γ (°) 90.0, 90.0, 90.0 
Resolution (Å) 61.83-1-79 (1.83-1.79) 
Rmerge (%) 1 5.9 (8.3) 
Rpim (%) 2 3.3 (29.7) 
I/σI 11.3 (2.2) 
Completeness (%) 99.6 (95.6) 
Multiplicity 4.0 (3.3) 
Total measured reflections 72556 (3586) 
Unique reflections 18173 (1072) 
Wilson B-factor (Å2) 25.15 
Refinement  
Resolution (Å) 43.50-1.79 
Rcryst/Rfree 3 20.9 /25.0 
Protein atoms 1308 
B factor (Å2) 38.47 
Rmsd bond length (Å) 0.021 







Figure 3.18- The 2F0-Fc density map of kLANA peptide region. The map is in blue contoured at 1.2 σ. 
 
 
Figure 3.19- Structure of USP7-kLANA chimera protein. (a) Cartoon representation of USP7-kLANA chimera 
protein, with the respectively structure with 90 degrees rotation on the right. The kLANA peptide is coloured in orange 
and USP7 strands are labelled. (b) kLANA peptide interaction region with USP7. On the right, detailed representation 
of interaction between USP7 (silver) and kLANA (orange) and the residues involved in the interaction are represented 
as a stick. 
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USP7-TRAF preferentially shown to interact with P/AxxS motifs 95. In kLANA this motif is formed 
by 977PGPS980, which we observed in the solved structure to interact with residues from the β7 strand 
(Figure 3.19b).  
kLANA interaction with USP7 is chiefly hydrophobic, similar to other USP7-TRAF domain partners. 
The binding region of USP7 contains a hydrophobic core centred on residues Trp165-Gly166-Phe167. The 
residue Trp and Phe have a sandwich conformation and make π interaction with the hydrophobic region of 
the kLANA peptide Pro977-Gly978- Pro979 (Figure 3.19). The main chain atoms make two hydrogen bonds 
at the centre by residue 166 (USP7) and residue 978 (kLANA).  
Another hydrogen bond, presumably determines the specificity, is made between the hydroxyl 
group of Ser980 (kLANA) and carboxyl group of Asp164 from USP7. Residue 164 from USP7 also makes 
another hydrogen bond with the main chain amide group of residue 980 from kLANA (Figure 3.20). 
Final interaction between the kLANA peptide and USP7 are between main chain carbonyl atom of 
residue 980 and side chain atom NH1 of Arg104, respectively. In addition, a unique interaction is made by 
the residue Gln976 at the start of kLANA peptide; two hydrogen bonds are made by the side chain atoms 
carboxyamide and carboxyl groups of Gln976 with carboxyl group and main chain amide group of Asn169 
(USP7), respectively. Furthermore hydrophobic residues, Phe118 and Ile154 from USP7 are in the vicinity 
of kLANA peptide making the USP7-kLANA interaction more hydrophobic (Figure 3.20).  
Figure 3.20- Schematic diagram illustrating the USP7-kLANA interactions, generated by LIGPLOT. The kLANA 
residues are displayed in blue and USP7 interacting residues are in orange. Hydrogen bonds are indicated by green 
dashed lines, while hydrophobic contacts are represented by a red arc with spokes radiating towards kLANA atoms 






4. DISCUSSION AND CONCLUSION 
 
The ubiquitin pathway is one of the major systems of protein regulation and has been implicated in 
the immune response, development, and programmed cell death 34,35,97. Viruses have a remarkable 
capacity to evolve and adapt in such a way that they can take advantage of the ubiquitin system for its own 
purposes, e.g. to modulate host proteins for viruses to enter and replicate 33. KSHV LANA protein is one of 
more examples which has the capacity to recruit a ubiquitin ligase complex for degradation of VHL and p53 
tumour suppressors 43.   
LANA was already shown to interact with Elongin BC complex, through binding with Elongin C via 
its BC-box motif located within its N-terminal domain. Furthermore, the LANA-Elongin BC complex 
assembles with a Cullin5/Rbx1 module to reconstitute a ubiquitin ligase complex (Figure 4.1) 43.  
 
 
Figure 4.1- Model for KSHV LANA assembles EC5S Ubiquitin complex to target restriction factors for 
degradation. Adapted from 43. 
 
The ubiquitin E3 ligase is the key enzyme in ubiquitination pathway, because it recognizes a 
specific protein substrate and catalyses the transfer of activated Ub to it. In the case of kLANA, the E3 
ligase from the Cullin-Ring family, Cul5 was preferentially recruited 43. The mechanism by which Cul5 
functions in this process remains unclear. To uncover other interaction partners will be important to gain 
insights into LANA recruitment of the ubiquitin assembly process.  
One potential partner is CBF-β protein, that is crucial for HIV-1 Vif recruitment to the ubiquitin-ligase 
complex 42,51,52, being functional similar to kLANA on targeted protein degradation. Vif recruitment process 
is well studied and the tertiary structure of Vif ubiquitin complex were recently resolved 49. Recent studies 
also indicated that, CBF-β binds with the N-terminal domain of Vif protein, which induces structural changes, 
to enable Cul5 to bind Vif and form a functional ubiquitin ligase complex 42. 
One of the goals of this work was to understand the mechanism behind kLANA recruitment of the 
EC5S ubiquitin complex. The starting point was to establish whether or not CBF-β interacts with kLANA. 
The pull down assays performed suggested no binding between CBF-β and kLANA, but neither with Elongin 
BC although it was previously identified to interact with the N-terminal domain of kLANA. Due to this, a 
control experiment was performed with Vif protein, which was able to pull down both CBF-β and Elongin C, 
which has validated the protocol being used for the study. Taking this into consideration, kLANA N-terminal 




One of the issues was the fact that the kLANA N-terminal domain is predicted to be intrinsically unfolded 
74. Due to the presence of an unstructured region in the N-terminus of LANA could impair formation of a 
complex, as well as contributing to poor expression, solubility and stability. Unlike kLANA, the homologous 
MHV-68 LANA (mLANA) was able to pull down Elongin BC, consistent with the previous study 44. It is worth 
mentioning the differences between kLANA and mLANA; while kLANA SOCS-box is spatially separated 
and present in the N-terminal domain (Elongin BC-box) and C-terminal domain (Cul5-box), mLANA has an 
unconventional SOCS-box which was present together at the C-terminal, which may make Elongin BC 
binding easier. Additional interaction partners from the ubiquitin complexes, like CBF-β and Cul5, were not 
able to be studied for mLANA truncations in the present studies. Further analyses are required to dissect 
the LANA-ubiquitin complexes. The results of this study suggested that kLANA does not interact directly 
with CBF-β and neither with Elongin BC. In contrast, mLANA is able to directly interact with Elongin BC. 
Apart from recruiting ubiquitin ligase complex, LANA also regulate the reversal of ubiquitination, 
through interaction with a deubiquitinating enzyme, USP7. LANA and p53 (tumour-suppressor protein) 
competes for the same pocket to bind in the USP7-TRAF domain. EBNA1 was also shown to bind to this 
USP7-TRAF region and showed to interfere with the binding and stabilization of p53 by USP7,  resulting in 
p53-mediated apoptosis in response to DNA damage 66. Other interesting feature was, USP7 enhancement 
on EBNA1 DNA binding activity.  
EBNA1 is the closest homolog protein from the gammaherpesvirus family of LANA and was 
previously shown that USP7 modulates the replication of KSHV latent episomal DNA 69. For this reason, 
the possibility of USP7 enhance LANA DNA binding was investigated. EMSAs results for both kLANA and 
mLANA, indicated that USP7 does not affect LANA’s DNA binding activity.  
A recent publication reported the X-ray crystal structure of kLANA bound to DNA, which shows an 
asymmetric binding, different from the EBNA1 DNA complex 24,98. Since DNA binding mechanisms are 
different compared to kLANA and EBNA1, might explain why USP7 enhances DNA binding in EBNA1 but 
not in kLANA.  
Previously, residues 971-986 of kLANA were shown to be interacting with USP7 69. However by 
further analysing the sequence, a conserved USP7 binding motif 978PGPS981 was present within amino acid 
residues 971-986 in kLANA. Another such motif 258PPTS262 is found in the N-terminal domain of kLANA, 
which is also likely to interact with USP7 95. Similarly, homologous mLANA also contains USP7 binding 
motif 272PSTS275, but at the end of C-terminus, spatially differently located compared to kLANA and EBNA1.  
The crystal structure of USP7-kLANA complex revealed a novel finding. Until now it has been observed 
that USP7-TRAF preferentially interacts with P/AxxS motifs 64,65,75. Here our findings show that USP7 
recognizes a 976QPGPS980 motif in kLANA. Interesting, mLANA also possesses a glutamine within the USP7 
recognition motif, 271QPSTS275.  
Therefore, additional to the standard motif, LANA proteins include a glutamine (Gln977) to establish 
hydrogen bonds with Asn169 of USP7, making Gln the new member of the recognition site in USP7 motif. 
To understand why kLANA utilizes this additional residue to establish extra hydrogen bonds with USP7, the 
previously mapped USP7-p53 interactions 64 was compared to USP7-kLANA interactions. 
The p53 peptide (358`EPGGSR´363) with an identical peptide-binding motif (PGGS), has an identical 





Figure 4.2- Comparison between kLANA and p53 peptides. kLANA is displayed in cyan and p53 in green. PDB 
code of P53 structure: 2FOO.  
 
 
Figure 4.3- Schematic diagram illustrating the USP7-kLANA interactions on the left and USP7-p53 interactions 
on the right. kLANA residues are displayed in blue, p53 residues in green and USP7 interacting residues in orange. 
Hydrogen bonds are indicated by green broken lines, while hydrophobic contacts are represented by a red arc with 
spokes radiating towards kLANA or p53 atoms to which they contact. The contacted atoms are showed with spoke 
radiating back.  
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For a more detailed analysis, LIGPLOTplus was again used to generate a schematic diagram of 
USP7-kLANA and USP7-p53 interactions, highlighting with a red circle similar interactions between the 
structures (Figure 4.3). Overall, the residues and the type of contacts made by USP7 with the peptides are 
similar. The main differences between kLANA and p53 on USP7 binding are the additional hydrogen bonds 
established between the carboxyamide group of kLANA Gln976 and the side chain carbonyl and main chain 
amino group of USP7 Asn169. The common features between kLANA and p53 peptides interaction with 
USP7 is the hydrophobic contacts centred on 165WGF167 and additional two hydrogen bonds made by 
residues Asp164 and Arg104. 
In summary, the USP7-TRAF domain has a structure that resembles the TRAF/MATH domain 
forming an eight anti-parallel β-sheet. Extensive structural and biochemical studies have shown that all of 
the USP7-peptide complex structures are interacting through the P/AxxS standard motif and mainly through 
the β7 strand of USP7. Most of the solved structures of USP7 complex showed that the peptides do not 
form any direct contacts with USP7-NTD outside of P/AxxS region. For the first time, glutamine residue 
from kLANA is shown to be part of the USP7 binding motif. Interestingly, also mLANA has glutamine residue 
as a part of the USP7 binding motif. A similar motif was found in two other herpesviruses, Saimiriine 
herpesvirus 2 and Bovine herpesvirus 4, indicating a common feature within the herpesvirus family. LANA 
may use the additional interaction residues to compete with USP7’s natural substrates like p53. In 
concurrence, ITC analysis revealed a kLANA peptide has 3.6-fold higher affinity than p53 for USP7 
(Unpublished data of Dr. Rajesh Ponnusamy, SVL, ITQB). 
 Since USP7 plays a vital role in p53 regulation, disturbances by kLANA interaction with USP7 may 
lead to a positive regulation of USP7, which in turns stabilizes the tumour-suppressor protein p53. The 
availability of high resolution structures will help to search for potential drug-like molecule screening and for 
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Figure S1 – Map illustration of the vectors used for cloning in this study. Design of the reporter vector a) pET47 b(+), 
encoding resistance for kanamycin with a 6xHis-Tag; b) pET49 b(+) encoding resistance for kanamycin with a GST-6xHis-Tag 
and c) pNEATH encoding resistance for ampicillin with a 6xHis-Tag. The desired genes were cloned in the Multiple Cloning Site 
(MCS) region.  


































Figure S2 – Fluorescence- based thermal shift analysis of USP7-TRAF truncation alone and in complex with three peptides. 
Thermofluor-based protein-unfolding curves of a) USP7-TRAF, b) USP7-k16, c) USP7-k10 and d) USP7-p53 for accessing the thermal 
stability effect of buffer and pH. The thermofluor experiment was prepared as described in 2.8, using 2.5 µg of protein and a 5-fold (final 
concentration) of SYPRO Orange. The experiment was performed from 20 °C to 90 °C in increments of 1 °C. 
 
 
 
 
 
 
 
 
